Tetraphase Pharmaceuticals Inc Hits New 52-Week High at $12.32 (TTPH)
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) hit a new 52-week high during trading on Tuesday, Analyst Ratings Network reports. The stock traded as high as $12.32 and last traded at $11.80, with a volume of 93,220 shares trading hands. The stock had previously closed at $11.38.
A number of analysts have recently weighed in on TTPH shares. Analysts at JMP Securities raised their price target on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from $12.00 to $16.00 in a research note to investors on Tuesday. They now have a “market outperform” rating on the stock. Separately, analysts at Needham & Company reiterated a “buy” rating on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research note to investors on Tuesday. They now have a $15.00 price target on the stock, up previously from $12.00. Finally, analysts at WBB Securities initiated coverage on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research note to investors on Monday. They set a “speculative buy” rating on the stock. Seven investment analysts have rated the stock with a buy rating, Tetraphase Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $15.20.
In other Tetraphase Pharmaceuticals news, major shareholder Ventures Vi Lp Cmea unloaded 100,000 shares of Tetraphase Pharmaceuticals stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $10.20, for a total value of $1,020,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Tetraphase Pharmaceuticals has a one year low of $7.00 and a one year high of $11.77. The stock’s 50-day moving average is $9.56 and its 200-day moving average is $8.27. The company’s market cap is $243.3 million.
Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.